ClinicalTrials.gg
CompletedNCT01756157Updated Jun 3, 2021Results posted

Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks

A Phase 2 interventional study of CINRYZE with rHuPH20 in Hereditary Angioedema (HAE), sponsored by Shire. Completed at 23 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-06-03.

Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing C1 esterase inhibitor (human) in Angioedemas, Hereditary — 1 open to participants now, 1 under way, none of them phase 3. C1 esterase inhibitor (human) · Angioedemas, Hereditary.

Enrollment
5th of 11
47 · median 32
Started
2013
the only one that year
Phase 2
8 of 11
1 open now
Registered
8th of 11
by date
Lead sponsor
5 of 11
Shire

Among the 11 studies testing C1 esterase inhibitor (human) in Angioedemas, Hereditary, this one is the 5th largest by enrollment, is the only one that started in 2013, is one of 8 in phase 2, and was the 8th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

1 of the 11 studies testing C1 esterase inhibitor (human) in Angioedemas, Hereditary is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About C1 esterase inhibitor (human)

C1 esterase inhibitor (human): first FDA approval 2008 (Cinryze), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing C1 esterase inhibitor (human) in Angioedemas, Hereditary, or all of them as a file.
02

Study summary

The primary objectives of the study are to evaluate the safety, tolerability, and efficacy of two doses of CINRYZE with recombinant human hyaluronidase (rHuPH20) administered by subcutaneous (SC) injection to prevent angioedema attacks.

03

Conditions studied

  • Hereditary Angioedema (HAE)

Keywords

  • Crossover
  • C1 esterase inhibitor
  • Prevention
  • C1 inhibitor
  • Hereditary Angioedema
  • Subcutaneous
  • Recombinant human hyaluronidase
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be ≥12 years of age.
  • Have a confirmed diagnosis of Hereditary Angioedema.

Exclusion criteria

Exclusion Criteria:

  • Receipt of any C1 inhibitor (C1 INH) therapy or any blood products for treatment or prevention of an angioedema attack within 7 days before the first dose of study drug.
  • Be receiving prophylactic intravenous CINRYZE that exceeds 1000 units every 3 or 4 days (maximum weekly dose 2000 units).
  • Have received any androgen therapy (e.g., danazol, oxandrolone, stanozolol, testosterone) within 7 days prior to the first dose of study drug.
  • If female, have started taking or changed the dose of any hormonal regimen or hormone replacement therapy (i.e., estrogen/progestin containing products) within 3 months prior to the first dose of study drug.
  • History of allergic reaction to C1 INH products, including CINRYZE or other blood products.
  • History of abnormal blood clotting.
  • Have a known allergy to hyaluronidase or any other ingredient in the study formulation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    SC CINRYZE with rHuPH20 Dose Level 1 followed by Dose Level 2

    SC CINRYZE with rHuPH20 Dose Level 1 twice weekly (every 3 or 4 days) for 8 weeks followed by SC CINRYZE with rHuPH20 Dose Level 2 twice weekly (every 3 or 4 days) for 8 weeks.

    Biological: CINRYZE with rHuPH20

  • Experimental
    SC CINRYZE with rHuPH20 Dose Level 2 followed by Dose Level 1

    SC CINRYZE with rHuPH20 Dose Level 2 twice weekly (every 3 or 4 days) for 8 weeks followed by SC CINRYZE with rHuPH20 Dose Level 1 twice weekly (every 3 or 4 days) for 8 weeks.

    Biological: CINRYZE with rHuPH20

Interventions

06

What researchers measure

Primary outcomes

  1. Normalized Number of Angioedema Attacks During the Treatment Period

    Angioedema attack was defined as the participant-reported indication of symptoms or signs such as swelling or pain at any location following a report of no swelling or pain on the previous day. Manifestations of an attack that progress from one site to another, prior to complete resolution, was considered a single attack. Attacks that began to regress and then worsened before complete resolution was also considered one attack. Participants who were dosed but did not have any attacks in the period were assigned a value of zero. The number of attacks was normalized for the number of days participants participated in a given period and expressed as the monthly frequency.

    Time frame: From Visit 1 (Week 1) up to Visit 16 (Week 8) during each treatment period

Secondary outcomes

  1. Cumulative Attack-severity During the Treatment Period

    Cumulative Attack-severity score was the sum of maximum symptom severity recorded for each angioedema attack, determined on the last day of symptoms and recorded as None=0, Mild=1, Moderate=2, and Severe=3 and summing over the unique attacks, yields a Cumulative Attack-severity score. None: no angioedema attack symptom; Mild: the angioedema attack symptom was noticeable to the participant but was easily tolerated and did not interfere with routine activities; Moderate: the angioedema attack symptom interfered with work/school or the ability to participate in family life and social activities; Severe: the angioedema attack symptom significantly limited the participant's ability to attend work/school or participate in family life and social activities. Cumulative attack-severity was normalized for the number of days participants participated in a given period and expressed as the monthly frequency. The scores ranged from 0 to 168 and higher scores represent worse symptoms.

    Time frame: From Visit 1 (Week 1) up to Visit 16 (Week 8) during each treatment period

  2. Cumulative Daily-severity During the Treatment Period

    Cumulative Daily-severity score was the sum of the severity scores recorded for every day of reported symptoms during the treatment period. Severity scores were recorded as None=0, Mild=1, Moderate=2, and Severe=3. None: no angioedema attack symptom; Mild: the angioedema attack symptom was noticeable to the participant but was easily tolerated and did not interfere with routine activities; Moderate: the angioedema attack symptom interfered with work/school or the ability to participate in family life and social activities; Severe: the angioedema attack symptom significantly limited the participant's ability to attend work/school or participate in family life and social activities. Cumulative daily severity was normalized for the number of days participants participated in a given period and expressed as the monthly frequency. The scores ranged from 0 to 168 and higher scores represent worse symptoms.

    Time frame: From Visit 1 (Week 1) up to Visit 16 (Week 8) during each treatment period

  3. Cumulative Symptomatic Days During the Treatment Period

    Cumulative symptomatic days was defined as the sum of the symptomatic days of each angioedema attack reported during the treatment period. Participants who were dosed but did not have any attacks in the period were assigned a value of zero. Cumulative symptomatic days was normalized for the number of days participants participated in a given period and expressed as the monthly frequency.

    Time frame: From Visit 1 (Week 1) up to Visit 16 (Week 8) during each treatment period

  4. Number of Angioedema Attacks Requiring Acute Treatment During the Treatment Period

    Angioedema attack was defined as the participant-reported indication of symptoms or signs such as swelling or pain at any location following a report of no swelling or pain on the previous day. Manifestations of an attack that progress from one site to another, prior to complete resolution, was considered a single attack. Attacks that began to regress and then worsened before complete resolution was also considered one attack. Participants who were dosed but did not have any attacks in the period were assigned a value of zero. The number of attacks was normalized for the number of days participants participated in a given period and expressed as the monthly frequency.

    Time frame: From Visit 1 (Week 1) up to Visit 16 (Week 8) during each treatment period

07

Results

Posted Jun 12, 2015
Limitations and caveats
Results of efficacy endpoints (time to first angioedema attack, effects of C1 inhibitor and C4 levels on clinical outcome during treatment period) were not reported due to early termination of the study but later completed for safety data.

Participant flow

This study was conducted at 24 sites (United States=20, Europe=4) between 04 February 2013 (first participant dosed) and 13 September 2013 (last participant contact). Of 52 screened participants, 47 were randomized and treated. Screen failure reasons were consent withdrawn by 1 participant and violation of eligibility criteria by 4 participants.

First Intervention Period
Participant flow — First Intervention Period
MilestoneTreatment Sequence A/BTreatment Sequence B/A
Started2324
Completed2222
Not completed12
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up02
Washout Period (at Least 7 Days)
Participant flow — Washout Period (at Least 7 Days)
MilestoneTreatment Sequence A/BTreatment Sequence B/A
Started2222
Completed2222
Not completed00
Second Intervention Period
Participant flow — Second Intervention Period
MilestoneTreatment Sequence A/BTreatment Sequence B/A
Started2222
Completed2222
Not completed00

Outcome measures

PrimaryNormalized Number of Angioedema Attacks During the Treatment Period

Angioedema attack was defined as the participant-reported indication of symptoms or signs such as swelling or pain at any location following a report of no swelling or pain on the previous day. Manifestations of an attack that progress from one site to another, prior to complete resolution, was considered a single attack. Attacks that began to regress and then worsened before complete resolution was also considered one attack. Participants who were dosed but did not have any attacks in the period were assigned a value of zero. The number of attacks was normalized for the number of days participants participated in a given period and expressed as the monthly frequency.

Time frame:
From Visit 1 (Week 1) up to Visit 16 (Week 8) during each treatment period
Reported as:
Mean · angioedema attacks
Normalized Number of Angioedema Attacks During the Treatment Period
angioedema attacksTreatment A (1000 U CINRYZE + 24000 U rHuPH20)Treatment B (2000 U CINRYZE + 48000 U rHuPH20)
Normalized Number of Angioedema Attacks During the Treatment Period1.58 (0.88 to 2.29)0.97 (0.41 to 1.53)
Statistical analysis
  • Treatment A (1000 U CINRYZE + 24000 U rHuPH20) vs Treatment B (2000 U CINRYZE + 48000 U rHuPH20) · Paired t-test, 2 sided · p = 0.0523 · Mean difference: -0.61 · 95% CI -1.23 to 0.01
SecondaryCumulative Attack-severity During the Treatment Period

Cumulative Attack-severity score was the sum of maximum symptom severity recorded for each angioedema attack, determined on the last day of symptoms and recorded as None=0, Mild=1, Moderate=2, and Severe=3 and summing over the unique attacks, yields a Cumulative Attack-severity score. None: no angioedema attack symptom; Mild: the angioedema attack symptom was noticeable to the participant but was easily tolerated and did not interfere with routine activities; Moderate: the angioedema attack symptom interfered with work/school or the ability to participate in family life and social activities; Severe: the angioedema attack symptom significantly limited the participant's ability to attend work/school or participate in family life and social activities. Cumulative attack-severity was normalized for the number of days participants participated in a given period and expressed as the monthly frequency. The scores ranged from 0 to 168 and higher scores represent worse symptoms.

Time frame:
From Visit 1 (Week 1) up to Visit 16 (Week 8) during each treatment period
Reported as:
Mean · Score on a scale
Cumulative Attack-severity During the Treatment Period
Score on a scaleTreatment A (1000 U CINRYZE + 24000 U rHuPH20)Treatment B (2000 U CINRYZE + 48000 U rHuPH20)
Cumulative Attack-severity During the Treatment Period3.14 ± 3.791.81 ± 2.55
SecondaryCumulative Daily-severity During the Treatment Period

Cumulative Daily-severity score was the sum of the severity scores recorded for every day of reported symptoms during the treatment period. Severity scores were recorded as None=0, Mild=1, Moderate=2, and Severe=3. None: no angioedema attack symptom; Mild: the angioedema attack symptom was noticeable to the participant but was easily tolerated and did not interfere with routine activities; Moderate: the angioedema attack symptom interfered with work/school or the ability to participate in family life and social activities; Severe: the angioedema attack symptom significantly limited the participant's ability to attend work/school or participate in family life and social activities. Cumulative daily severity was normalized for the number of days participants participated in a given period and expressed as the monthly frequency. The scores ranged from 0 to 168 and higher scores represent worse symptoms.

Time frame:
From Visit 1 (Week 1) up to Visit 16 (Week 8) during each treatment period
Reported as:
Mean · Score on a scale
Cumulative Daily-severity During the Treatment Period
Score on a scaleTreatment A (1000 U CINRYZE + 24000 U rHuPH20)Treatment B (2000 U CINRYZE + 48000 U rHuPH20)
Cumulative Daily-severity During the Treatment Period4.63 ± 5.792.81 ± 4.42
SecondaryCumulative Symptomatic Days During the Treatment Period

Cumulative symptomatic days was defined as the sum of the symptomatic days of each angioedema attack reported during the treatment period. Participants who were dosed but did not have any attacks in the period were assigned a value of zero. Cumulative symptomatic days was normalized for the number of days participants participated in a given period and expressed as the monthly frequency.

Time frame:
From Visit 1 (Week 1) up to Visit 16 (Week 8) during each treatment period
Reported as:
Mean · days
Cumulative Symptomatic Days During the Treatment Period
daysTreatment A (1000 U CINRYZE + 24000 U rHuPH20)Treatment B (2000 U CINRYZE + 48000 U rHuPH20)
Cumulative Symptomatic Days During the Treatment Period3.06 ± 3.512.14 ± 3.30
SecondaryNumber of Angioedema Attacks Requiring Acute Treatment During the Treatment Period

Angioedema attack was defined as the participant-reported indication of symptoms or signs such as swelling or pain at any location following a report of no swelling or pain on the previous day. Manifestations of an attack that progress from one site to another, prior to complete resolution, was considered a single attack. Attacks that began to regress and then worsened before complete resolution was also considered one attack. Participants who were dosed but did not have any attacks in the period were assigned a value of zero. The number of attacks was normalized for the number of days participants participated in a given period and expressed as the monthly frequency.

Time frame:
From Visit 1 (Week 1) up to Visit 16 (Week 8) during each treatment period
Reported as:
Mean · angioedema attacks
Number of Angioedema Attacks Requiring Acute Treatment During the Treatment Period
angioedema attacksTreatment A (1000 U CINRYZE + 24000 U rHuPH20)Treatment B (2000 U CINRYZE + 48000 U rHuPH20)
Number of Angioedema Attacks Requiring Acute Treatment During the Treatment Period0.99 ± 1.510.43 ± 0.89

Adverse events

Collected over From the time of first dose of study drug up to 7 days after the last dose of study drug within each treatment period (8 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A (1000 U CINRYZE + 24000 U rHuPH20)—0/44 (0%)42/44 (95.5%)
Treatment B (2000 U CINRYZE + 48000 U rHuPH20)—0/46 (0%)46/46 (100%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventTreatment A (1000 U CINRYZE + 24000 U rHuPH20)Treatment B (2000 U CINRYZE + 48000 U rHuPH20)
Injection site reactionsGeneral disorders37/4440/46
Hereditary angioedemaCongenital, familial and genetic disorders32/4428/46
Injection site extravasationGeneral disorders4/449/46
FatigueGeneral disorders4/441/46
NasopharyngitisInfections and infestations4/441/46
Muscle spasmsMusculoskeletal and connective tissue disorders3/442/46
HeadacheNervous system disorders2/443/46
ContusionInjury, poisoning and procedural complications2/440/46
Chest discomfortGeneral disorders2/440/46
Injury associated with deviceGeneral disorders2/440/46

Baseline characteristics

Intent-to-treat safety (ITT-S) population included all participants who received any amount of study drug.

Age, Continuous
Age, Continuous(years)Entire Study Population
Mean39.0 ± 14.6
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female33
Male14
08

Study locations

23 sites
  • ViroPharma Investigational Site
    Birmingham, Alabama 35209, United States
  • ViroPharma Investigational Site
    Scottsdale, Arizona 85251, United States
  • ViroPharma Investigational Site
    Bentonville, Arkansas 72712, United States
  • ViroPharma Investigational Site
    Walnut Creek, California 94598, United States
  • ViroPharma Investigational Site
    Colorado Springs, Colorado 80907, United States
  • ViroPharma Investigational Site
    Tampa, Florida 33613, United States
  • ViroPharma Investigational Site
    Boston, Massachusetts 02114, United States
  • ViroPharma Investigational Site
    Las Vegas, Nevada 89106, United States
  • ViroPharma Investigational Site
    Mineola, New York 11501, United States
  • ViroPharma Investigational Site
    Cincinnati, Ohio 45267, United States
  • ViroPharma Investigational Site
    Columbus, Ohio 43235, United States
  • ViroPharma Investigational Site
    Lake Oswego, Oregon 97035, United States
  • ViroPharma Investigational Site
    Hershey, Pennsylvania 17033, United States
  • ViroPharma Investigational Site
    Pittsburgh, Pennsylvania 15241, United States
  • ViroPharma Investigational Site
    Knoxville, Tennessee 37909, United States
  • ViroPharma Investigational Site
    Dallas, Texas 75231, United States
  • ViroPharma Investigational Site
    Spokane, Washington 99204, United States
  • ViroPharma Investigational Site
    Berlin, Germany
  • ViroPharma Investigational Site
    Essen, Germany
  • ViroPharma Investigational Site
    Mainz, Germany
  • ViroPharma Investigational Site
    Munchen, Germany
  • ViroPharma Investigational Site
    Barcelona, Spain
  • ViroPharma Investigational Site
    Jonkoping, Sweden
09

References and documents

Publications

  • Riedl MA, Lumry WR, Li HH, Banerji A, Bernstein JA, Ba M, Bjrkander J, Magerl M, Maurer M, Rockich K, Chen H, Schranz J. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy Asthma Proc. 2016 Nov;37(6):489-500. doi: 10.2500/aap.2016.37.4006. PubMed 27931305 ↗
  • Beard N, Frese M, Smertina E, Mere P, Katelaris C, Mills K. Interventions for the long-term prevention of hereditary angioedema attacks. Cochrane Database Syst Rev. 2022 Nov 3;11(11):CD013403. doi: 10.1002/14651858.CD013403.pub2. PubMed 36326435 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2013 to primary completion in Sep 2013, 7 months.

Results were first posted in Jun 2015, 1 year 8 months after primary completion. A results delay was requested in Feb 2015.

Of 17 phase 2 interventional studies under Angioedemas, Hereditary, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2012
First posted
Dec 25, 2012
StartActual
Feb 4, 2013
Primary completionActual
Sep 13, 2013
CompletionActual
Sep 13, 2013
Results delay requested
Feb 19, 2015
Results first posted
Jun 12, 2015
Last update
Jun 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01756157
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Dec 25, 2012
Start date
Feb 4, 2013
Primary completion
Sep 13, 2013
Completion
Sep 13, 2013
Results posted
Jun 12, 2015
Last update
Jun 3, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: C1 esterase inhibitor (human) · Hyaluronidase (human recombinant)

Start the discussion